EBCC 2024

European Breast Cancer Conference

Interviews and expert commentary from EBCC 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.

EBCC 2024 logo
Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
Audio Journal of Oncology

Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab

ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC

28 August 2025
15:48
Read more about Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
← All EBCC interviews← Browse all episodes